A Phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 1, 1999, Pages 127-135

  Groves, Morris D ^a   Maor, Moshe H ^a   Meyers, Christina ^a   Kyritsis, Athanassios P ^a   Jaeckle, Kurt A ^a   Yung, W K Alfred ^a   Sawaya, Raymond E ^a   Hess, Kenneth ^a   Bruner, Janet M ^a   Peterson, Pamela ^a   Levin, Victor A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Accelerated fractionated radiotherapy; Bromodeoxyuridine (BrdU); Glioblastoma

Indexed keywords

BROXURIDINE; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SKIN TOXICITY; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BROMODEOXYURIDINE; COGNITION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; LOMUSTINE; MALE; MIDDLE AGED; PROCARBAZINE; RADIATION-SENSITIZING AGENTS; REOPERATION; VINCRISTINE;

EID: 0032801217     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00122-4     Document Type: Article

References (64)

1. Walker M.D., Alexander E.J., Hunt;, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas A cooperative clinical trial . J Neurosurg. 49:1978;333-343.
2. Kristiansen K., Hagen S., Kollevold T., et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 47:1981;649-652.
3. Thames H.D.J., Peters L.J., Withers H.R., et al. Accelerated fractionation vs hyperfractionation Rationales for several treatments per day . Int J Radiat Oncol Biol Phys. 9:1983;127-138.
4. Fowler J.F. Review Total doses in fractionated radiotherapy - implications of new radiobiological data . Int J Radiat Biol Relat Stud Phys Chem Med. 46:1984;103-120.
5. Keim H., Potthoff P.C., Schmidt K., et al. Survival and quality of life after continuous accelerated radiotherapy of glioblastomas. Radiother Oncol. 9:1987;21-26.
6. Horiot J.C., van den Bogaert W., Ang K.K., et al. European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day A 1978-1987 survey . Front Radiat Ther Oncol. 22:1988;149-161.
7. Levin V.A., Maor M.H., Thall P.F., et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 33:1995;357-364.
8. Levin V.A., Silver P., Hannigan J., et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas NCOG 6G61 final report . Int J Radiat Oncol Biol Phys. 18:1990;321-324.
9. Levin V.A., Wilson C.B., Davis R., et al. A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg. 51:1979;526-532.
10. Urtasun R., Band P., Chapman J.D., et al. Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med. 294:1976;1364-1367.
11. Urtasun R., Feldstein M.L., Partington J., et al. Radiation and nitroimidazoles in supratentorial high grade gliomas A second clinical trial . Br J Cancer. 46:1982;101-108.
12. Sack H., Calcanis A., Godehardt E., et al. [Postoperative radiotherapy of astrocytomas grade 3 and 4 with the radiosensitizer misonidazole End results of a multicentric controlled German study] [in German] . Strahlentherapie. 158:1982;466-469.
13. Green S.B., Byar D.P., Strike T.A. Randomized comparisons of BCNU, streptozotocin, radiosensitizer, and fractionation of radiotherapy in the postoperative treatment of malignant glioma. Pro Am Soc Clin Oncol. 3:(A1018):1984;260. (Abstr).
14. Bleehen N.M., Wiltshire C.R., Plowman P.N., et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma. Br J Cancer. 43:1981;436-442.
15. Goffman T.E., Dachowski L.J., Bobo H., et al. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. J Clin Oncol. 10:1992;264-268.
16. Phillips T.L., Levin V.A., Ahn D.K., et al. Evaluation of bromodeoxyuridine in glioblastoma multiforme A Northern California Cancer Center Phase II study . Int J Radiat Oncol Biol Phys. 21:1991;709-714.
17. Maor M.H., Levin V.A. Malignant gliomas. John M.J., Philips T., Legha S. Chemoradiation an integrated approach to cancer treatment . 1993;191-203 Lea & Febiger, Philadelphia.
18. Djordjevic B., Djordjevic O. Chromosomal aberrations in synchronized mammalian cells treated with 5-bromo-deoxyuridine and irradiated by ultra-violet light. Nature. 206:1965;1165-1166.
19. Zimbrick J.D., Ward J.F., Myers L.S. Jr. Studies on the chemical basis of cellular radiosensitization by 5-bromouracil substitution in DNA. II. Pulse- and steady state radiolysis of bromouracil-substituted and unsubstituted DNA. Int J Radiat Biol Relat Stud Phys Chem Med. 16:1969;525-534.
20. McGinn C.J., Shewach D.S., Lawrence T.S. Radiosensitizing nucleosides. J Natl Cancer Inst. 88:1996;1193-1203.
21. Kinsella T.J., Dobson P.P., Mitchell J.B., et al. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys. 13:1987;733-739.
22. Ling L.L., Ward J.F. Radiosensitization of Chinese hamster V79 cells by bromodeoxyuridine substitution of thymidine Enhancement of radiation-induced toxicity and DNA strand break production by monofilar and bifilar substitution . Radiat Res. 121:1990;76-83.
23. Miller E.M., Fowler J.F., Kinsella T.J. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine. Radiat Res. 131:1992;81-89.
24. Miller E.M., Fowler J.F., Kinsella T.J. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. II. Radiosensitization of human colon cancer cells by bromodeoxyuridine. Radiat Res. 131:1992;90-97.
25. Iliakis G., Kurtzman S. Mechanism of radiosensitization by halogenated pyrimidines Bromodeoxyuridine and beta-arabinofuranosyladenine affect similar subsets of radiation-induced potentially lethal lesions in plateau-phase Chinese hamster ovary cells . Radiat Res. 127:1991;45-51.
26. Iliakis G., Kurtzman S., Pantelias G., et al. Mechanism of radiosensitization by halogenated pyrimidines Effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing . Radiat Res. 119:1989;286-304.
27. Schneider D.O., Johns R.M. Enhancement of radiation-induced mitotic inhibition by BUdR incorporation in L-cells. Radiat Res. 28:1966;657-667.
28. Goz B. The effects of incorporation of 5-halogenated deoxyuridines into the DNA of eukaryotic cells. Pharmacol Rev. 29:1977;249-272.
29. Phuphanich S., Levin E.M., Levin V.A. Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors. Int J Radiat Oncol Biol Phys. 10:1984;1769-1772.
30. Burger P.C., Scheithauer B.W., Vogel F.S. Surgical pathology of the nervous system and its coverings. 1991;Churchill Livingstone, New York.
31. Wechsler D. Wechsler Adult Intelligence Scale-Revised. 1981;The Psychological Corporation, San Antonio.
32. Lezak M.D. Neuropsychological assessment. 1995;Oxford University Press, New York.
33. Hannay H.J., Levin H.S. Selective reminding test An examination of the equivalence of four forms . J Clin Exp Neuropsychol. 7:1985;251-263.
34. Brandt J. The Hopkins verbal learning test Development of a new memory test with six equivalent forms . Clin Neuropsychol. 5:1991;125-142.
35. Benton A.L. Revised Visual Retention Test. 1974;The Psychological Corporation, San Antonio.
36. Benton A.L., Hamsher K.D. Multilingual Aphasia Examination. 1989;AJA Associates, Iowa City, IA.
37. Benton A.L., Hamsher K.D., Varney N.R., Spreen O. Contributions to neuropsychological assessment a clinical manual . 1983;Oxford University Press, New York.
38. Weitzner M.A., Meyers C.A., Gelke C.K., et al. The Functional Assessment of Cancer Therapy (FACT) scale Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors . Cancer. 75:1995;1151-1161.
39. Beck A.T., Steer R.A. Beck Depression Inventory. 1987;The Psychological Corporation, San Antonio.
40. Kaplan E.L., Meier P.J. Nonparametric estimates from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
41. Fleming T.R., Harrington D.P. Counting processes and survival analysis. 1991;John Wiley & Sons, New York.
42. Cox D.R. Regression models and life tables. J R Stat Soc. 34:1972;187-220.
43. Grambsch P.M., Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals Biometrika. 81:1994;515-552.
44. Therneau T.M., Grambsch P.M., Fleming T.R. Martingale-based residuals for survival models. Biometrika. 77:1990;147-160.
45. Cleveland W.S. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 74:1979;596-610.
46. Mehta C.R. The exact analysis of contingency tables in medical research. Stat Methods Med Res. 3:1994;135-156.
47. Anastasi A. Psychological testing. 1982;Macmillan, New York.
48. Chelune G.J., Naugle R.I., Luders H. Individual change after epilepsy surgery Practice effects and base-rate information . Neuropsychology. 7:1993;41-52.
49. Levin V.A., Wara W.M., Davis R.L., et al. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg. 63:1985;218-223.
50. Prados M.D., Scott C.B., Rotman M., et al. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma . Int J Radiat Oncol Biol Phys. 40:1998;653-659.
51. Hoshino T. Radiotherapy of malignant brain tumors with bromouridine in view of cell kinetics. Jpn J Cancer Clin. 20:1974;67-70.
52. Sano K., Hoshino T., Nagai M. Radiosensitization of brain tumor cells with a thymidine analogue (bromouridine). J Neurosurg. 28:1968;530-538.
53. Sano K., Sato F., Hoshino T., et al. Experimental and clinical studies of radiosensitizers in brain tumors, with special reference to BUdR-antimetabolite continuous regional infusion-radiation therapy (BAR therapy). Neurol MedicoChirurg. 7:1965;51-72.
54. Levin V.A., Prados M.R., Wara W.M., et al. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys. 32:1995;75-83.
55. Simpson J.R., Horton J., Scott C., et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials . Int J Radiat Oncol Biol Phys. 26:1993;239-244.
56. Harsh G.R. 4th, Levin V.A., Gutin P.H., et al. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery. 21:1987;615-621.
57. Salcman M. Resection and reoperation in neuro-oncology Rationale and approach . Neurol Clin. 3:1985;831-842.
58. Burger P.C., Mahley M.S.J., Dudka L., et al. The morphologic effects of radiation administered therapeutically for intracranial gliomas A postmortem study of 25 cases . Cancer. 44:1979;1256-1272.
59. Marks J.E., Baglan R.J., Prassad S.C., et al. Cerebral radionecrosis Incidence and risk in relation to dose, time, fractionation and volume . Int J Radiat Oncol Biol Phys. 7:1981;243-252.
60. Leibel S.A., Sheline G.E. Radiation therapy for neoplasms of the brain. J Neurosurg. 66:1980;1-22.
61. Levin V.A., Leibel S.A., Gutin P.H. Neoplasms of the central nervous system. DeVita V.T. Jr, Hellman S., Rosenberg S.A. Cancer principles and practice of oncology . 1997;2022-2073 Lippincott-Raven, Philadelphia.
62. Scheibel R.S., Meyers C.A., Levin V.A. Cognitive dysfunction following surgery for intracerebral glioma Influence of histopathology, lesion location, and treatment . J Neurooncol. 30:1996;61-69.
63. Meyers C.A. Issues of quality of life in neuro-oncology. Vecht C.J. Handbook of clinical neurology. 1997;389-409 Elsevier, Amsterdam.
64. Levin V.A., Wara W.M., Davis R.L., et al. Northern California Oncology Group protocol 6G91 Response to treatment with radiation therapy and seven-drug chemotherapy in patients with glioblastoma multiforme . Cancer Treat Rep. 70:1986;739-743.